General Information of Drug (ID: DMBVIKY)

Drug Name
Cilostamide Drug Info
Synonyms
cilostamide; 68550-75-4; ciloalamide; OPC 3689; Cilostamide [INN]; N-Cyclohexyl-N-methyl-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide; Cilostamidum [INN-Latin]; Cilostamida [INN-Spanish]; UNII-45S5605Q18; OPC 3869; CHEMBL34431; NCGC00015269-03; N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide; 45S5605Q18; Butanamide, N-cyclohexyl-4-((1,2-dihydro-2-oxo-6-quinolinyl)oxy)-N-methyl-; N-Cyclohexyl-N-methyl-4-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)butanamide; DSSTox_RID_80698; DSSTox_CID_25140; DSSTox_GSID_45140
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2753
ChEBI ID
CHEBI:92503
CAS Number
CAS 68550-75-4
TTD Drug ID
DMBVIKY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 3 (PDE3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [3]
Oxtriphylline DMLHSE3 Cough MD12 Approved [3]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [4]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [5]
Olprinone DMWBQKU Heart failure BD10-BD13 Approved [6]
Inamrinone Lactate DMRMFP4 Cardiac disease BA00-BE2Z Approved [7]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [3]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [8]
Tipelukast DMS9BDQ Asthma CA23 Phase 2 [9]
RPL-554 DMLD4VQ Allergic rhinitis CA08.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5167).
2 Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001 Jan;12(1):79-83.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
5 In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
6 Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
7 Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
8 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
9 Company report (MediciNova)
10 Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.